Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICARuS II: Intraperitoneal vs Intravenous Chemotherapy After Surgery for Malignant Peritoneal Mesothelioma
NCT06057935Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2023
- Primary completion
- Sep 2028
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pemetrexed, Cisplatin micelle injection (HA132) in malignant peritoneal mesothelioma (MPM), sponsored by Memorial Sloan Kettering Cancer Center. Started Sep 2023; status: recruiting.
02
Drugs
pemetrexedCisplatin micelle injection (HA132)
03
Conditions
malignant peritoneal mesothelioma (MPM)
Beyond the preview
Go deeper on NCT06057935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06057935.